{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T02:03:15Z","timestamp":1776996195627,"version":"3.51.4"},"reference-count":89,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,13]]},"DOI":"10.7759\/cureus.73593","type":"journal-article","created":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T13:24:58Z","timestamp":1731504298000},"source":"Crossref","is-referenced-by-count":2,"title":["Navigating Pompe Disease Assessment: A Comprehensive Scoping Review"],"prefix":"10.7759","author":[{"given":"Leticia","family":"Nunes Campos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Israel","family":"Davila Rivera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daiana M","family":"Iba\u00f1ez Alegre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabiana N","family":"del Puerto Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00f3nica","family":"Garrido San Juan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federico","family":"Fernandez Zelcer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Delfina","family":"Borgobello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayla","family":"Gerk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura F","family":"Sosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcos M","family":"Miretti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorgelina","family":"Stegmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carina F","family":"Arg\u00fcelles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3390\/children9091404","article-title":"The clinical management of Pompe disease: a pediatric perspective","volume":"9","author":"Marques JS","year":"2022","unstructured":"Marques JS. The clinical management of Pompe disease: a pediatric perspective. Children (Basel). 2022, 9:4. 10.3390\/children9091404","journal-title":"Children (Basel)"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.18632\/aging.103794","article-title":"Pompe disease: pathogenesis, molecular genetics and diagnosis","volume":"12","author":"Taverna S","year":"2020","unstructured":"Taverna S, Cammarata G, Colomba P, et al.. Pompe disease: pathogenesis, molecular genetics and diagnosis. Aging (Albany NY). 2020, 12:15856-74. 10.18632\/aging.103794","journal-title":"Aging (Albany NY)"},{"key":"ref3","unstructured":"Variant database. (2023). Accessed. August 26, 2023: https:\/\/www.pompevariantdatabase.nl\/pompe_mutations_list.php."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/humu.24148","article-title":"Update of the Pompe variant database for the prediction of clinical phenotypes: novel disease-associated variants, common sequence variants, and results from newborn screening","volume":"42","author":"de Faria DO","year":"2021","unstructured":"de Faria DO, 't Groen SL, Hoogeveen-Westerveld M, Nino MY, van der Ploeg AT, Bergsma AJ, Pijnappel WW. Update of the Pompe variant database for the prediction of clinical phenotypes: novel disease-associated variants, common sequence variants, and results from newborn screening. Hum Mutat. 2021, 42:119-34. 10.1002\/humu.24148","journal-title":"Hum Mutat"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.21037\/atm.2019.04.13","article-title":"Molecular genetics of Pompe disease: a comprehensive overview","volume":"7","author":"Peruzzo P","year":"2019","unstructured":"Peruzzo P, Pavan E, Dardis A. Molecular genetics of Pompe disease: a comprehensive overview. Ann Transl Med. 2019, 7:278. 10.21037\/atm.2019.04.13","journal-title":"Ann Transl Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-021-01864-8","article-title":"Genotype-phenotype correlation of 17 cases of Pompe disease in Spanish patients and identification of 4 novel GAA variants","volume":"16","author":"Hern\u00e1ndez-Ar\u00e9valo P","year":"2021","unstructured":"Hern\u00e1ndez-Ar\u00e9valo P, Santotoribio JD, Delarosa-Rodr\u00edguez R, et al.. Genotype-phenotype correlation of 17 cases of Pompe disease in Spanish patients and identification of 4 novel GAA variants. Orphanet J Rare Dis. 2021, 16:233. 10.1186\/s13023-021-01864-8","journal-title":"Orphanet J Rare Dis"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2021.02.013","article-title":"Late onset Pompe disease in India - beyond the Caucasian phenotype","volume":"31","author":"Puri RD","year":"2021","unstructured":"Puri RD, Setia N, N V, et al.. Late onset Pompe disease in India - beyond the Caucasian phenotype. Neuromuscul Disord. 2021, 31:431-41. 10.1016\/j.nmd.2021.02.013","journal-title":"Neuromuscul Disord"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.21037\/atm.2019.07.24","article-title":"Multisystem late onset Pompe disease (LOPD): an update on clinical aspects","volume":"7","author":"Toscano A","year":"2019","unstructured":"Toscano A, Rodolico C, Musumeci O. Multisystem late onset Pompe disease (LOPD): an update on clinical aspects. Ann Transl Med. 2019, 7:284. 10.21037\/atm.2019.07.24","journal-title":"Ann Transl Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2020.03.007","article-title":"Is it Pompe disease? Australian diagnostic considerations","volume":"30","author":"Tchan M","year":"2020","unstructured":"Tchan M, Henderson R, Kornberg A, et al.. Is it Pompe disease? Australian diagnostic considerations. Neuromuscul Disord. 2020, 30:389-99. 10.1016\/j.nmd.2020.03.007","journal-title":"Neuromuscul Disord"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3233\/JND-220819","article-title":"A multidisciplinary perspective addressing the diagnostic challenges of late-onset Pompe disease in the Arabian Peninsula region developed from an expert group meeting","volume":"9","author":"Al Shehri A","year":"2022","unstructured":"Al Shehri A, Al-Asmi A, Al Salti AM, et al.. A multidisciplinary perspective addressing the diagnostic challenges of late-onset Pompe disease in the Arabian Peninsula region developed from an expert group meeting. J Neuromuscul Dis. 2022, 9:661-73. 10.3233\/JND-220819","journal-title":"J Neuromuscul Dis"},{"key":"ref11","unstructured":"Outcome and Process Assessment, Health Care. (2020). Accessed. August 26, 2023: https:\/\/www.ncbi.nlm.nih.gov\/mesh\/68010043."},{"key":"ref12","unstructured":"Assessment tools in Pompe disease. a scoping review protocol. (2022). Accessed: August 26, 2023: https:\/\/osf.io\/j7n9c\/."},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.7326\/M18-0850","article-title":"PRISMA Extension for Scoping Reviews (PRISMA-ScR): checklist and explanation","volume":"169","author":"Tricco AC","year":"2018","unstructured":"Tricco AC, Lillie E, Zarin W, et al.. PRISMA Extension for Scoping Reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med. 2018, 169:467-73. 10.7326\/M18-0850","journal-title":"Ann Intern Med"},{"key":"ref14","unstructured":"Diagnostic Screening Programs. (2023). Accessed. August 26, 2023: https:\/\/www.ncbi.nlm.nih.gov\/mesh\/2027878.."},{"key":"ref15","unstructured":"Diagnosis. (2022). Accessed. August 26, 2023: https:\/\/www.ncbi.nlm.nih.gov\/mesh\/68003933.."},{"key":"ref16","unstructured":"Follow-Up Studies. (2022). Accessed. August 26, 2023: https:\/\/www.ncbi.nlm.nih.gov\/mesh\/68005500.."},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2014-310164","article-title":"LOPED study: looking for an early diagnosis in a late-onset Pompe disease high-risk population","volume":"87","author":"Musumeci O","year":"2016","unstructured":"Musumeci O, la Marca G, Spada M, et al.. LOPED study: looking for an early diagnosis in a late-onset Pompe disease high-risk population. J Neurol Neurosurg Psychiatry. 2016, 87:5-11. 10.1136\/jnnp-2014-310164","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-019-1037-1","article-title":"Is early detection of late-onset Pompe disease a pneumologist's affair? A lesson from an Italian screening study","volume":"14","author":"Confalonieri M","year":"2019","unstructured":"Confalonieri M, Vitacca M, Scala R, et al.. Is early detection of late-onset Pompe disease a pneumologist's affair? A lesson from an Italian screening study. Orphanet J Rare Dis. 2019, 14:62. 10.1186\/s13023-019-1037-1","journal-title":"Orphanet J Rare Dis"},{"key":"ref19","unstructured":"EndNote | The best reference management tool. (2020). Accessed. November 16, 2022: https:\/\/endnote.com\/.."},{"key":"ref20","unstructured":"Online, collaborative spreadsheets. Accessed. August 26, 2023: https:\/\/workspace.google.com\/intl\/eng\/products\/sheets\/."},{"key":"ref21","unstructured":"Forms. Accessed. August 26, 2023: https:\/\/workspace.google.com\/intl\/eng\/lp\/forms\/.."},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1097\/XEB.0000000000000050","article-title":"Guidance for conducting systematic scoping reviews","volume":"13","author":"Peters MD","year":"2015","unstructured":"Peters MD, Godfrey CM, Khalil H, McInerney P, Parker D, Soares CB. Guidance for conducting systematic scoping reviews. Int J Evid Based Healthc. 2015, 13:141-6. 10.1097\/XEB.0000000000000050","journal-title":"Int J Evid Based Healthc"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-016-0116-4","article-title":"A scoping review on the conduct and reporting of scoping reviews","volume":"16","author":"Tricco AC","year":"2016","unstructured":"Tricco AC, Lillie E, Zarin W, et al.. A scoping review on the conduct and reporting of scoping reviews. BMC Med Res Methodol. 2016, 16:15. 10.1186\/s12874-016-0116-4","journal-title":"BMC Med Res Methodol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2016-0280E","article-title":"Management of confirmed newborn-screened patients with Pompe disease across the disease spectrum","volume":"140","author":"Kronn DF","year":"2017","unstructured":"Kronn DF, Day-Salvatore D, Hwu WL, et al.. Management of confirmed newborn-screened patients with Pompe disease across the disease spectrum. Pediatrics. 2017, 140:S24-45. 10.1542\/peds.2016-0280E","journal-title":"Pediatrics"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2016-0280C","article-title":"Newborn screening for Pompe disease","volume":"140","author":"Bodamer OA","year":"2017","unstructured":"Bodamer OA, Scott CR, Giugliani R. Newborn screening for Pompe disease. Pediatrics. 2017, 140:S4-S13. 10.1542\/peds.2016-0280C","journal-title":"Pediatrics"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.34763\/jmotherandchild.20202402si.2001.000002","article-title":"Advances in diagnosis and management of Pompe disease","volume":"24","author":"Davison JE","year":"2020","unstructured":"Davison JE. Advances in diagnosis and management of Pompe disease. J Mother Child. 2020, 24:3-8. 10.34763\/jmotherandchild.20202402si.2001.000002","journal-title":"J Mother Child"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.3390\/ijns6020031","article-title":"Newborn screening for Pompe disease","volume":"6","author":"Sawada T","year":"2020","unstructured":"Sawada T, Kido J, Nakamura K. Newborn screening for Pompe disease. Int J Neonatal Screen. 2020, 6:31. 10.3390\/ijns6020031","journal-title":"Int J Neonatal Screen"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1007\/s11940-022-00736-1","article-title":"Pompe disease: a clinical, diagnostic, and therapeutic overview","volume":"24","author":"Stevens D","year":"2022","unstructured":"Stevens D, Milani-Nejad S, Mozaffar T. Pompe disease: a clinical, diagnostic, and therapeutic overview. Curr Treat Options Neurol. 2022, 24:573-88. 10.1007\/s11940-022-00736-1","journal-title":"Curr Treat Options Neurol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2016-0280D","article-title":"The initial evaluation of patients after positive newborn screening: recommended algorithms leading to a confirmed diagnosis of Pompe disease","volume":"140","author":"Burton BK","year":"2017","unstructured":"Burton BK, Kronn DF, Hwu WL, Kishnani PS. The initial evaluation of patients after positive newborn screening: recommended algorithms leading to a confirmed diagnosis of Pompe disease. Pediatrics. 2017, 140:S14-23. 10.1542\/peds.2016-0280D","journal-title":"Pediatrics"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1038\/gim.2017.190","article-title":"Moonlighting newborn screening markers: the incidental discovery of a second-tier test for Pompe disease","volume":"20","author":"Tortorelli S","year":"2018","unstructured":"Tortorelli S, Eckerman JS, Orsini JJ, et al.. Moonlighting newborn screening markers: the incidental discovery of a second-tier test for Pompe disease. Genet Med. 2018, 20:840-6. 10.1038\/gim.2017.190","journal-title":"Genet Med"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.3390\/books978-3-0365-0581-7","article-title":"Newborn screening for Pompe disease","author":"Hwu WL","year":"2021","unstructured":"Hwu WL, Chien YH, Wang R. Newborn screening for Pompe disease. Hwu WL, Chien YH, Wang R (ed): MDPI,  Basel, Switzerland; 2021. 10.3390\/books978-3-0365-0581-7"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-022-02545-w","article-title":"Expert Group Consensus on early diagnosis and management of infantile-onset Pompe disease in the Gulf Region","volume":"17","author":"Al-Hassnan Z","year":"2022","unstructured":"Al-Hassnan Z, Hashmi NA, Makhseed N, Omran TB, Al Jasmi F, Teneiji AA. Expert Group Consensus on early diagnosis and management of infantile-onset Pompe disease in the Gulf Region. Orphanet J Rare Dis. 2022, 17:388. 10.1186\/s13023-022-02545-w","journal-title":"Orphanet J Rare Dis"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.a.38333","article-title":"Next generation deep sequencing corrects diagnostic pitfalls of traditional molecular approach in a patient with prenatal onset of Pompe disease","volume":"173","author":"Tsai AC","year":"2017","unstructured":"Tsai AC, Hung YW, Harding C, Koeller DM, Wang J, Wong LC. Next generation deep sequencing corrects diagnostic pitfalls of traditional molecular approach in a patient with prenatal onset of Pompe disease. Am J Med Genet A. 2017, 173:2500-4. 10.1002\/ajmg.a.38333","journal-title":"Am J Med Genet A"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1515\/jpem-2019-0477","article-title":"Identification of two novel variants in GAA underlying infantile-onset Pompe disease in two Pakistani families","volume":"33","author":"Ullah A","year":"2020","unstructured":"Ullah A, Zubaida B, Cheema HA, Naeem M. Identification of two novel variants in GAA underlying infantile-onset Pompe disease in two Pakistani families. J Pediatr Endocrinol Metab. 2020, 33:553-6. 10.1515\/jpem-2019-0477","journal-title":"J Pediatr Endocrinol Metab"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1038\/s41436-019-0527-9","article-title":"Clinical characteristics and genotypes in the ADVANCE baseline data set, a comprehensive cohort of US children and adolescents with Pompe disease","volume":"21","author":"Kishnani PS","year":"2019","unstructured":"Kishnani PS, Gibson JB, Gambello MJ, et al.. Clinical characteristics and genotypes in the ADVANCE baseline data set, a comprehensive cohort of US children and adolescents with Pompe disease. Genet Med. 2019, 21:2543-51. 10.1038\/s41436-019-0527-9","journal-title":"Genet Med"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2019.03.048","article-title":"A genetic modifier of symptom onset in Pompe disease","volume":"43","author":"Bergsma AJ","year":"2019","unstructured":"Bergsma AJ, In 't Groen SL, van den Dorpel JJ, et al.. A genetic modifier of symptom onset in Pompe disease. EBioMedicine. 2019, 43:553-61. 10.1016\/j.ebiom.2019.03.048","journal-title":"EBioMedicine"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-38025-0","article-title":"PDGF-BB serum levels are decreased in adult onset Pompe patients","volume":"9","author":"Fern\u00e1ndez-Sim\u00f3n E","year":"2019","unstructured":"Fern\u00e1ndez-Sim\u00f3n E, Carrasco-Rozas A, Gallardo E, et al.. PDGF-BB serum levels are decreased in adult onset Pompe patients. Sci Rep. 2019, 9:2139. 10.1038\/s41598-018-38025-0","journal-title":"Sci Rep"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.4103\/0366-6999.225056","article-title":"Identification of seven novel mutations in the acid alpha-glucosidase gene in five Chinese patients with late-onset Pompe disease","volume":"131","author":"Liu HX","year":"2018","unstructured":"Liu HX, Pu CQ, Shi Q, Zhang YT, Ban R. Identification of seven novel mutations in the acid alpha-glucosidase gene in five Chinese patients with late-onset Pompe disease. Chin Med J (Engl). 2018, 131:448-53. 10.4103\/0366-6999.225056","journal-title":"Chin Med J (Engl)"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-017-0722-1","article-title":"Identification of GAA variants through whole exome sequencing targeted to a cohort of 606 patients with unexplained limb-girdle muscle weakness","volume":"12","author":"Johnson K","year":"2017","unstructured":"Johnson K, T\u00f6pf A, Bertoli M, et al.. Identification of GAA variants through whole exome sequencing targeted to a cohort of 606 patients with unexplained limb-girdle muscle weakness. Orphanet J Rare Dis. 2017, 12:173. 10.1186\/s13023-017-0722-1","journal-title":"Orphanet J Rare Dis"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1002\/humu.23878","article-title":"GAA variants and phenotypes among 1,079 patients with Pompe disease: data from the Pompe Registry","volume":"40","author":"Reuser AJ","year":"2019","unstructured":"Reuser AJ, van der Ploeg AT, Chien YH, et al.. GAA variants and phenotypes among 1,079 patients with Pompe disease: data from the Pompe Registry. Hum Mutat. 2019, 40:2146-64. 10.1002\/humu.23878","journal-title":"Hum Mutat"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-023-01886-5","article-title":"Cipaglucosidase alfa: first approval","volume":"83","author":"Blair HA","year":"2023","unstructured":"Blair HA. Cipaglucosidase alfa: first approval. Drugs. 2023, 83:739-45. 10.1007\/s40265-023-01886-5","journal-title":"Drugs"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.3390\/cells11030334","article-title":"Six-minute walk distance is a useful outcome measure to detect motor decline in treated late-onset Pompe disease patients","volume":"11","author":"Claeys KG","year":"2022","unstructured":"Claeys KG, D'Hondt A, Fache L, Peers K, Depuydt CE. Six-minute walk distance is a useful outcome measure to detect motor decline in treated late-onset Pompe disease patients. Cells. 2022, 11:34. 10.3390\/cells11030334","journal-title":"Cells"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-29170-7","article-title":"Quantitative muscle MRI to follow up late onset Pompe patients: a prospective study","volume":"8","author":"Figueroa-Bonaparte S","year":"2018","unstructured":"Figueroa-Bonaparte S, Llauger J, Segovia S, et al.. Quantitative muscle MRI to follow up late onset Pompe patients: a prospective study. Sci Rep. 2018, 8:10898. 10.1038\/s41598-018-29170-7","journal-title":"Sci Rep"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1177\/0883073816665549","article-title":"Cognitive development in infantile-onset Pompe disease under very early enzyme replacement therapy","volume":"31","author":"Lai CJ","year":"2016","unstructured":"Lai CJ, Hsu TR, Yang CF, Chen SJ, Chuang YC, Niu DM. Cognitive development in infantile-onset Pompe disease under very early enzyme replacement therapy. J Child Neurol. 2016, 31:1617-21. 10.1177\/0883073816665549","journal-title":"J Child Neurol"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2015.10.078","article-title":"Very early treatment for infantile-onset Pompe disease contributes to better outcomes","volume":"169","author":"Yang CF","year":"2016","unstructured":"Yang CF, Yang CC, Liao HC, et al.. Very early treatment for infantile-onset Pompe disease contributes to better outcomes. J Pediatr. 2016, 169:174-80. 10.1016\/j.jpeds.2015.10.078","journal-title":"J Pediatr"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-016-8219-8","article-title":"Survival and long-term outcomes in late-onset Pompe disease following alglucosidase alfa treatment: a systematic review and meta-analysis","volume":"264","author":"Schoser B","year":"2017","unstructured":"Schoser B, Stewart A, Kanters S, et al.. Survival and long-term outcomes in late-onset Pompe disease following alglucosidase alfa treatment: a systematic review and meta-analysis. J Neurol. 2017, 264:621-30. 10.1007\/s00415-016-8219-8","journal-title":"J Neurol"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2017.03.001","article-title":"Newborn screening for six lysosomal storage disorders in a cohort of Mexican patients: three-year findings from a screening program in a closed Mexican health system","volume":"121","author":"Navarrete-Mart\u00ednez JI","year":"2017","unstructured":"Navarrete-Mart\u00ednez JI, Lim\u00f3n-Rojas AE, Gayt\u00e1n-Garc\u00eda MJ, et al.. Newborn screening for six lysosomal storage disorders in a cohort of Mexican patients: three-year findings from a screening program in a closed Mexican health system. Mol Genet Metab. 2017, 121:16-21. 10.1016\/j.ymgme.2017.03.001","journal-title":"Mol Genet Metab"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2022.1053559","article-title":"Opportunities and challenges for newborn screening and early diagnosis of rare diseases in Latin America","volume":"13","author":"Giugliani R","year":"2022","unstructured":"Giugliani R, Castillo Taucher S, Hafez S, et al.. Opportunities and challenges for newborn screening and early diagnosis of rare diseases in Latin America. Front Genet. 2022, 13:59. 10.3389\/fgene.2022.1053559","journal-title":"Front Genet"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2023.107654","article-title":"Pilot study of newborn screening for six lysosomal diseases in Brazil","volume":"140","author":"Kubaski F","year":"2023","unstructured":"Kubaski F, Sousa I, Amorim T, et al.. Pilot study of newborn screening for six lysosomal diseases in Brazil. Mol Genet Metab. 2023, 140:54. 10.1016\/j.ymgme.2023.107654","journal-title":"Mol Genet Metab"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.3390\/ijns6040090","article-title":"Neonatal screening for MPS disorders in Latin America: a survey of pilot initiatives","volume":"6","author":"Kubaski F","year":"2020","unstructured":"Kubaski F, Sousa I, Amorim T, et al.. Neonatal screening for MPS disorders in Latin America: a survey of pilot initiatives. Int J Neonatal Screen. 2020, 6:90. 10.3390\/ijns6040090","journal-title":"Int J Neonatal Screen"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.c.31899","article-title":"Newborn screening in Latin America: a brief overview of the state of the art","volume":"187","author":"Borrajo GJ","year":"2021","unstructured":"Borrajo GJ. Newborn screening in Latin America: a brief overview of the state of the art. Am J Med Genet C Semin Med Genet. 2021, 187:322-8. 10.1002\/ajmg.c.31899","journal-title":"Am J Med Genet C Semin Med Genet"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.3390\/ijns7010006","article-title":"Expanded newborn screening and genomic sequencing in Latin America and the resulting social justice and ethical considerations","volume":"7","author":"Cabello JF","year":"2021","unstructured":"Cabello JF, Novoa F, Huff HV, Colombo M. Expanded newborn screening and genomic sequencing in Latin America and the resulting social justice and ethical considerations. Int J Neonatal Screen. 2021, 7:6. 10.3390\/ijns7010006","journal-title":"Int J Neonatal Screen"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2021.136080","article-title":"The future of newborn screening for lysosomal disorders","volume":"760","author":"Wasserstein MP","year":"2021","unstructured":"Wasserstein MP, Orsini JJ, Goldenberg A, Caggana M, Levy PA, Breilyn M, Gelb MH. The future of newborn screening for lysosomal disorders. Neurosci Lett. 2021, 760:80. 10.1016\/j.neulet.2021.136080","journal-title":"Neurosci Lett"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.3390\/ijns6030055","article-title":"Establishing Pompe disease newborn screening: the role of industry","volume":"6","author":"Keutzer JM","year":"2020","unstructured":"Keutzer JM. Establishing Pompe disease newborn screening: the role of industry. Int J Neonatal Screen. 2020, 6:55. 10.3390\/ijns6030055","journal-title":"Int J Neonatal Screen"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2018.05.007","article-title":"229th ENMC international workshop: limb girdle muscular dystrophies - nomenclature and reformed classification Naarden, the Netherlands, 17-19 March 2017","volume":"28","author":"Straub V","year":"2018","unstructured":"Straub V, Murphy A, Udd B. 229th ENMC international workshop: limb girdle muscular dystrophies - nomenclature and reformed classification Naarden, the Netherlands, 17-19 March 2017. Neuromuscul Disord. 2018, 28:702-10. 10.1016\/j.nmd.2018.05.007","journal-title":"Neuromuscul Disord"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1038\/s41431-020-00752-2","article-title":"Enzymatic diagnosis of Pompe disease: lessons from 28 years of experience","volume":"29","author":"Ni\u00f1o MY","year":"2021","unstructured":"Ni\u00f1o MY, Wijgerde M, de Faria DO, et al.. Enzymatic diagnosis of Pompe disease: lessons from 28 years of experience. Eur J Hum Genet. 2021, 29:434-46. 10.1038\/s41431-020-00752-2","journal-title":"Eur J Hum Genet"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1002\/mus.21376","article-title":"Screening for Pompe disease using a rapid dried blood spot method: experience of a clinical diagnostic laboratory","volume":"40","author":"Goldstein JL","year":"2009","unstructured":"Goldstein JL, Young SP, Changela M, et al.. Screening for Pompe disease using a rapid dried blood spot method: experience of a clinical diagnostic laboratory. Muscle Nerve. 2009, 40:32-6. 10.1002\/mus.21376","journal-title":"Muscle Nerve"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2014.07.014","article-title":"Methods of diagnosis of patients with Pompe disease: data from the Pompe Registry","volume":"113","author":"Kishnani PS","year":"2014","unstructured":"Kishnani PS, Amartino HM, Lindberg C, Miller TM, Wilson A, Keutzer J. Methods of diagnosis of patients with Pompe disease: data from the Pompe Registry. Mol Genet Metab. 2014, 113:84-91. 10.1016\/j.ymgme.2014.07.014","journal-title":"Mol Genet Metab"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1212\/NXG.0000000000000623","article-title":"Investigating late-onset Pompe prevalence in neuromuscular medicine academic practices: the IPaNeMA study","volume":"7","author":"Wencel M","year":"2021","unstructured":"Wencel M, Shaibani A, Goyal NA, et al.. Investigating late-onset Pompe prevalence in neuromuscular medicine academic practices: the IPaNeMA study. Neurol Genet. 2021, 7:e623. 10.1212\/NXG.0000000000000623","journal-title":"Neurol Genet"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aam6375","article-title":"Rescue of Pompe disease in mice by AAV-mediated liver delivery of secretable acid \u03b1-glucosidase","volume":"9","author":"Puzzo F","year":"2017","unstructured":"Puzzo F, Colella P, Biferi MG, et al.. Rescue of Pompe disease in mice by AAV-mediated liver delivery of secretable acid \u03b1-glucosidase. Sci Transl Med. 2017, 9:75. 10.1126\/scitranslmed.aam6375","journal-title":"Sci Transl Med"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.21037\/atm.2019.05.02","article-title":"Liver depot gene therapy for Pompe disease","volume":"7","author":"Kishnani PS","year":"2019","unstructured":"Kishnani PS, Koeberl DD. Liver depot gene therapy for Pompe disease. Ann Transl Med. 2019, 7:288. 10.21037\/atm.2019.05.02","journal-title":"Ann Transl Med"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.21037\/atm.2019.04.67","article-title":"Progress and challenges of gene therapy for Pompe disease","volume":"7","author":"Ronzitti G","year":"2019","unstructured":"Ronzitti G, Collaud F, Laforet P, Mingozzi F. Progress and challenges of gene therapy for Pompe disease. Ann Transl Med. 2019, 7:287. 10.21037\/atm.2019.04.67","journal-title":"Ann Transl Med"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2014.00177","article-title":"Pompe disease: from pathophysiology to therapy and back again","volume":"6","author":"Lim JA","year":"2014","unstructured":"Lim JA, Li L, Raben N. Pompe disease: from pathophysiology to therapy and back again. Front Aging Neurosci. 2014, 6:177. 10.3389\/fnagi.2014.00177","journal-title":"Front Aging Neurosci"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1007\/s13760-016-0738-7","article-title":"New mutations and genotype-phenotype correlation in late-onset Pompe patients","volume":"117","author":"Bekircan-Kurt CE","year":"2017","unstructured":"Bekircan-Kurt CE, G\u00fcne\u015f HN, Yildiz FG, Saka E, Tan E, Erdem-\u00d6zdamar S. New mutations and genotype-phenotype correlation in late-onset Pompe patients. Acta Neurol Belg. 2017, 117:269-75. 10.1007\/s13760-016-0738-7","journal-title":"Acta Neurol Belg"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2018.11.013","article-title":"Skeletal alterations, developmental delay and new mutations in juvenile-onset Pompe disease","volume":"29","author":"Guevara-Campos J","year":"2019","unstructured":"Guevara-Campos J, Gonz\u00e1lez-Guevara L, Cauli O. Skeletal alterations, developmental delay and new mutations in juvenile-onset Pompe disease. Neuromuscul Disord. 2019, 29:192-7. 10.1016\/j.nmd.2018.11.013","journal-title":"Neuromuscul Disord"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1002\/humu.23854","article-title":"Extension of the Pompe mutation database by linking disease-associated variants to clinical severity","volume":"40","author":"Ni\u00f1o MY","year":"2019","unstructured":"Ni\u00f1o MY, In 't Groen SL, Bergsma AJ, et al.. Extension of the Pompe mutation database by linking disease-associated variants to clinical severity. Hum Mutat. 2019, 40:1954-67. 10.1002\/humu.23854","journal-title":"Hum Mutat"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1590\/1678-4685-GMB-2018-0092","article-title":"Sensitivity, advantages, limitations, and clinical utility of targeted next-generation sequencing panels for the diagnosis of selected lysosomal storage disorders","volume":"42","author":"M\u00e1laga DR","year":"2019","unstructured":"M\u00e1laga DR, Brusius-Facchin AC, Siebert M, et al.. Sensitivity, advantages, limitations, and clinical utility of targeted next-generation sequencing panels for the diagnosis of selected lysosomal storage disorders. Genet Mol Biol. 2019, 42:197-206. 10.1590\/1678-4685-GMB-2018-0092","journal-title":"Genet Mol Biol"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2018.03.011","article-title":"Targeted gene panel screening is an effective tool to identify undiagnosed late onset Pompe disease","volume":"28","author":"Savarese M","year":"2018","unstructured":"Savarese M, Torella A, Musumeci O, et al.. Targeted gene panel screening is an effective tool to identify undiagnosed late onset Pompe disease. Neuromuscul Disord. 2018, 28:586-91. 10.1016\/j.nmd.2018.03.011","journal-title":"Neuromuscul Disord"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2023.107565","article-title":"Pompe disease ascertained through The Lantern Project, 2018-2021: next-generation sequencing and enzymatic testing to overcome obstacles to diagnosis","volume":"139","author":"Sniderman King L","year":"2023","unstructured":"Sniderman King L, Pan Y, Nallamilli BR, et al.. Pompe disease ascertained through The Lantern Project, 2018-2021: next-generation sequencing and enzymatic testing to overcome obstacles to diagnosis. Mol Genet Metab. 2023, 139:65. 10.1016\/j.ymgme.2023.107565","journal-title":"Mol Genet Metab"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1111\/dmcn.13740","article-title":"Classic infantile Pompe patients approaching adulthood: a cohort study on consequences for the brain","volume":"60","author":"Ebbink BJ","year":"2018","unstructured":"Ebbink BJ, Poelman E, Aarsen FK, et al.. Classic infantile Pompe patients approaching adulthood: a cohort study on consequences for the brain. Dev Med Child Neurol. 2018, 60:579-86. 10.1111\/dmcn.13740","journal-title":"Dev Med Child Neurol"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2009.08.003","article-title":"Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants","volume":"99","author":"Kishnani PS","year":"2010","unstructured":"Kishnani PS, Goldenberg PC, DeArmey SL, et al.. Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants. Mol Genet Metab. 2010, 99:26-33. 10.1016\/j.ymgme.2009.08.003","journal-title":"Mol Genet Metab"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.c.31319","article-title":"Predicting cross-reactive immunological material (CRIM) status in Pompe disease using GAA mutations: lessons learned from 10 years of clinical laboratory testing experience","volume":"160","author":"Bali DS","year":"2012","unstructured":"Bali DS, Goldstein JL, Banugaria S, Dai J, Mackey J, Rehder C, Kishnani PS. Predicting cross-reactive immunological material (CRIM) status in Pompe disease using GAA mutations: lessons learned from 10 years of clinical laboratory testing experience. Am J Med Genet C Semin Med Genet. 2012, 160:40-9. 10.1002\/ajmg.c.31319","journal-title":"Am J Med Genet C Semin Med Genet"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2013.08.010","article-title":"A new assay for fast, reliable CRIM status determination in infantile-onset Pompe disease","volume":"111","author":"Wang Z","year":"2014","unstructured":"Wang Z, Okamoto P, Keutzer J. A new assay for fast, reliable CRIM status determination in infantile-onset Pompe disease. Mol Genet Metab. 2014, 111:92-100. 10.1016\/j.ymgme.2013.08.010","journal-title":"Mol Genet Metab"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.a.36110","article-title":"Timing of diagnosis of patients with Pompe disease: data from the Pompe registry","volume":"161","author":"Kishnani PS","year":"2013","unstructured":"Kishnani PS, Amartino HM, Lindberg C, Miller TM, Wilson A, Keutzer J. Timing of diagnosis of patients with Pompe disease: data from the Pompe registry. Am J Med Genet A. 2013, 161:2431-43. 10.1002\/ajmg.a.36110","journal-title":"Am J Med Genet A"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.a.35662","article-title":"How to describe the clinical spectrum in Pompe disease?","volume":"161","author":"G\u00fcng\u00f6r D","year":"2013","unstructured":"G\u00fcng\u00f6r D, Reuser AJ. How to describe the clinical spectrum in Pompe disease?. Am J Med Genet A. 2013, 161:399-400. 10.1002\/ajmg.a.35662","journal-title":"Am J Med Genet A"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1097\/01.gim.0000218152.87434.f3","article-title":"Pompe disease diagnosis and management guideline","volume":"8","author":"Kishnani PS","year":"2006","unstructured":"Kishnani PS, Steiner RD, Bali D, et al.. Pompe disease diagnosis and management guideline. Genet Med. 2006, 8:267-88. 10.1097\/01.gim.0000218152.87434.f3","journal-title":"Genet Med"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.36469\/jheor.2023.68157","article-title":"Quality of life with late-onset Pompe disease: qualitative interviews and general public utility estimation in the United Kingdom","volume":"10","author":"Hubig L","year":"2023","unstructured":"Hubig L, Sussex A-K, MacCulloch A, et al.. Quality of life with late-onset Pompe disease: qualitative interviews and general public utility estimation in the United Kingdom. J Health Econ Outcomes Res. 2023, 10:41-50. 10.36469\/jheor.2023.68157","journal-title":"J Health Econ Outcomes Res"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-021-01836-y","article-title":"Quality of life and its contributors among adults with late-onset Pompe disease in China","volume":"16","author":"Chen S","year":"2021","unstructured":"Chen S, Wang J, Zhu J, Chung RY, Dong D. Quality of life and its contributors among adults with late-onset Pompe disease in China. Orphanet J Rare Dis. 2021, 16:199. 10.1186\/s13023-021-01836-y","journal-title":"Orphanet J Rare Dis"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2021.11.145","article-title":"Living with Pompe disease in the UK: characterizing the patient journey and burden on physical, emotional and social quality of life","volume":"135","author":"Hughes D","year":"2022","unstructured":"Hughes D, Odedra K, Bashorum L, et al.. Living with Pompe disease in the UK: characterizing the patient journey and burden on physical, emotional and social quality of life. Mol Genet Metab. 2022, 135:59. 10.1016\/j.ymgme.2021.11.145","journal-title":"Mol Genet Metab"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-017-0983-2","article-title":"The humanistic burden of Pompe disease: are there still unmet needs? A systematic review","volume":"17","author":"Schoser B","year":"2017","unstructured":"Schoser B, Bilder DA, Dimmock D, Gupta D, James ES, Prasad S. The humanistic burden of Pompe disease: are there still unmet needs? A systematic review. BMC Neurol. 2017, 17:202. 10.1186\/s12883-017-0983-2","journal-title":"BMC Neurol"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2013.07.020","article-title":"The impact of informal care for patients with Pompe disease: an application of the CarerQol instrument","volume":"110","author":"Kanters TA","year":"2013","unstructured":"Kanters TA, van der Ploeg AT, Brouwer WB, Hakkaart L. The impact of informal care for patients with Pompe disease: an application of the CarerQol instrument. Mol Genet Metab. 2013, 110:281-6. 10.1016\/j.ymgme.2013.07.020","journal-title":"Mol Genet Metab"},{"key":"ref82","article-title":"Early prenatal diagnosis of lysosomal storage disorders by enzymatic and molecular analysis","volume":"23","author":"Li D","year":"20182024","unstructured":"Li D, Lin Y, Huang Y, et al.. Early prenatal diagnosis of lysosomal storage disorders by enzymatic and molecular analysis. Prenat Diagn [Internet. 20182024, 23:779-87.","journal-title":"Prenat Diagn [Internet"},{"key":"ref83","article-title":"Insight into the phenotype of infants with Pompe disease identified by newborn screening with the common c.-32-13T>G \u201clate-onset\u201d GAA variant","volume":"23","author":"Rairikar MV","year":"20172024","unstructured":"Rairikar MV, Case LE, Bailey LA, et al.. Insight into the phenotype of infants with Pompe disease identified by newborn screening with the common c.-32-13T>G \u201clate-onset\u201d GAA variant. Mol Genet Metab [Internet. 20172024, 23:99-107.","journal-title":"Mol Genet Metab [Internet"},{"key":"ref84","article-title":"Clinical and molecular characterization of infantile-onset Pompe disease in mainland Chinese patients: Identification of two common mutations","volume":"23","author":"Chen X","year":"20172024","unstructured":"Chen X, Liu T, Huang M, et al.. Clinical and molecular characterization of infantile-onset Pompe disease in mainland Chinese patients: Identification of two common mutations. Genet Test Mol Biomarkers [Internet. 20172024, 23:391-6.","journal-title":"Genet Test Mol Biomarkers [Internet"},{"key":"ref85","article-title":"A new mutation causing severe infantile-onset Pompe disease responsive to enzyme replacement therapy","volume":"23","author":"Moravej H","year":"20182024","unstructured":"Moravej H, Amirhakimi A, Showraki A, Amoozgar H, Hadipour Z, Nikfar G. A new mutation causing severe infantile-onset Pompe disease responsive to enzyme replacement therapy. Iran J Med Sci [Internet. 20182024, 23:218-22.","journal-title":"Iran J Med Sci [Internet"},{"key":"ref86","article-title":"Late-onset Pompe disease in France: molecular features and epidemiology from a nationwide study","volume":"23","author":"Semplicini C","year":"20182024","unstructured":"Semplicini C, Letard P, De Antonio M, et al.. Late-onset Pompe disease in France: molecular features and epidemiology from a nationwide study. J Inherit Metab Dis [Internet. 20182024, 23:937-46.","journal-title":"J Inherit Metab Dis [Internet"},{"key":"ref87","article-title":"Severe cardiac involvement is rare in patients with late-onset Pompe disease and the common c.-32-13T>G variant: Implications for newborn screening","volume":"23","author":"Herbert M","year":"20182024","unstructured":"Herbert M, Cope H, Li JS, Kishnani PS. Severe cardiac involvement is rare in patients with late-onset Pompe disease and the common c.-32-13T>G variant: Implications for newborn screening. J Pediatr [Internet. 20182024, 23:308-12.","journal-title":"J Pediatr [Internet"},{"key":"ref88","article-title":"First clinical and genetic description of a family diagnosed with late-onset Pompe disease from Costa Rica","volume":"23","author":"Torrealba-Acosta G","year":"20172024","unstructured":"Torrealba-Acosta G, Rodr\u00edguez-Roblero MC, Bogantes-Ledezma S, Carazo-C\u00e9spedes K, Desnuelle C. First clinical and genetic description of a family diagnosed with late-onset Pompe disease from Costa Rica. Neuromuscul Disord [Internet. 20172024, 23:951-5.","journal-title":"Neuromuscul Disord [Internet"},{"key":"ref89","article-title":"Identification a novel mononucleotide deletion mutation in GAA in pompe disease patients","volume":"16","author":"Ebrahimi M","year":"2017","unstructured":"Ebrahimi M, Behnam M, Behranvand-Jazi N, et al.. Identification a novel mononucleotide deletion mutation in GAA in pompe disease patients. J Res Med Sci [Internet. 2017, 16:100.","journal-title":"J Res Med Sci [Internet"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/233211-navigating-pompe-disease-assessment-a-comprehensive-scoping-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T13:25:05Z","timestamp":1731504305000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/233211-navigating-pompe-disease-assessment-a-comprehensive-scoping-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,13]]},"references-count":89,"URL":"https:\/\/doi.org\/10.7759\/cureus.73593","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11,13]]}}}